{
    "clinical_study": {
        "@rank": "70492", 
        "arm_group": [
            {
                "arm_group_label": "Pantovigar + Minoxidil 2%", 
                "arm_group_type": "Experimental", 
                "description": "Minoxidil 2% is given as background therapy in both arms"
            }, 
            {
                "arm_group_label": "Minoxidil 2% only", 
                "arm_group_type": "Other", 
                "description": "Minoxidil 2% is given as background therapy in both arms"
            }
        ], 
        "brief_summary": {
            "textblock": "Pantovigar - a high effective product designed primarily for the treatment of diffuse hair\n      loss in women as well as for the treatment of damaged hair, in the combined therapy can be\n      successfully applied in other types of alopecia.\n\n      The purpose of this study is to  evaluate efficacy and tolerability of combination therapy\n      Pantovigar plus 2% minoxidil vs 2% minoxidil. To collect tolerability data for combined\n      treatment Pantovigar plus 2% Minoxidil course therapy."
        }, 
        "brief_title": "A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Female Pattern Hair Loss", 
            "Androgenetic Alopecia (AGA)", 
            "Ludwig Type 1", 
            "Ludwig Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alopecia", 
                "Alopecia Areata"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patient complaint of hair loss and/or hair density reduction for more than 3\n             months.\n\n          -  More than 15 % of telogen frontoparietal hair as shown in the phototrichogram.\n\n        Exclusion Criteria:\n\n          -  Symptomatic diffuse alopecia (screening for iron and thyroid function, thyroid\n             stimulating hormon, triiodothyrine, ferritin , total iron-binding capacity)\n\n          -  Active or history of systemic  autoimmune disease, e.g. lupus erythematodes etc.\n\n          -  Hyperandrogenic alopecia (polycystic ovary syndrome, adrenogenital syndrome, tumors\n             with androgenic activity) (testosterone, prolactin hormone, androstenedione,\n             dehydroepiandrosterone)\n\n          -  Initiation or termination of hormone therapy within 6 months prior to entering study\n\n          -  Hormone therapy with androgenic action, e.g. norethisterone etc.\n\n          -  Pregnancy or lactation within 6 months prior to entering study\n\n          -  Alopecia areata\n\n          -  Scarring alopecia\n\n          -  Treatment with hair promoting agent within 3 months prior to entering study\n\n          -  Known hair loss after drug intake\n\n          -  Concomitant use of the drugs causing a hair  loss (e.g.  aromatase inhibitors,\n             thyreostatics, cytostatics, etc,)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01900041", 
            "org_study_id": "MRU20040_4002_1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pantovigar + Minoxidil 2%", 
                "description": "1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.", 
                "intervention_name": "Pantovigar", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Pantovigar + Minoxidil 2%", 
                    "Minoxidil 2% only"
                ], 
                "description": "1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.", 
                "intervention_name": "Minoxidil 2% only", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Minoxidil"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "119071"
                    }, 
                    "name": "Moscow Scientific Clinical Center of Dermatology and Cosmetology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "107076"
                    }, 
                    "name": "State Scientific Center of Dermatology and Cosmetology"
                }
            }
        ], 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Randomised, Open Label, Comparative Clinical Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss (Including AGA Ludwig's Type 1-2)", 
        "overall_official": {
            "affiliation": "LLC Merz Pharma, Russia", 
            "last_name": "Medical Expert", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Assessed by the Investigator using the results photo trichogram (TrichoScience). Responders are defined to fulfill at least one of the following criteria:\nReduction in the amount of telogen hair to 15% and below\nIncreasing hair growth density\nThickening of average hair diameter\nReduction in the amount of vellus hair in comparison with initial indicators", 
            "measure": "Rate of responders to the treatment", 
            "safety_issue": "No", 
            "time_frame": "Week 16-20 post baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01900041"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merz Pharmaceuticals GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "LLC Merz Pharma, Russia", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Merz Pharmaceuticals GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}